The complaint alleges that Aardvark Therapeutics and several company officers failed to disclose critical information within their registration statements and subsequent public filings between February 13, 2025, and May 14, 2026. According to the court filing, the defendants purportedly overstated the clinical and regulatory prospects of ARD-101, ultimately painting a false picture of the drug's safety profile to the market.
Aardvark Therapeutics Faces Class Action Over Alleged IPO Misstatements
Investors who purchased Aardvark Therapeutics stock following the company’s February 2025 initial public offering are now being recruited for a class action lawsuit. Filed by Bronstein, Gewirtz & Grossman, the litigation centers on claims that the firm misled shareholders regarding the safety and commercial viability of its lead drug candidate, ARD-101.
Legal representatives at Bronstein, Gewirtz & Grossman are inviting affected shareholders to participate in the case, which seeks to recover damages for losses sustained during the specified period. Investors interested in serving as lead plaintiff must file their requests with the court by October 13, 2026. The firm, which operates on a contingency fee basis, maintains that its focus remains on corporate accountability and the restoration of investor capital.
Comments (0)
No comments yet. Be the first!